AFMD News and Press, Affimed N.V. From 02/08/23

HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities ...

AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of clinical study during 2023 AFM24: Data updates from the three AFM24 ongoing studies are exp...

Affimed N.V. ( NASDAQ: AFMD )  is trading 2.5% higher premarket after it said on Thursday the French National Agency for the Safety of Medicines and Health Products had approved a clinical trial application for the phase 1 study of AFM28 in relapsed/refractory acute myel...

AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM) Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec....

AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS) Leukemia cell lysis was independent of differenc...

German biotech Affimed N.V. ( NASDAQ: AFMD ) lost ~26% pre-market Monday after announcing plans to focus its lead asset AFM13 as a combination therapy targeting certain cancers related to the immune system. The announcement comes after the company updated results from an investiga...

Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of...

AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients Patients had a median of seven prior lines of treatment; of note, all patients failed to demonstrate obj...

Review of clinical data and development plans for AFM13 in hematologic malignancies Live event and webcast on Saturday, December 10 at 4:00 p.m. CST HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Companyȁ...

Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. The clinical-stage biotech's stock closed at $2.45 on Wednesday before opening at $2.37 on Thursday. It fell to $2.0801, the stock's 52-week low, in t...